Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1537-1546

  Simons, Jonathan W ^a,b   Jaffee, Elizabeth M ^a   Weber, Christine E ^a   Levitsky, Hyam I ^a   Nelson, William G ^a,b   Carducci, Michael A ^a,b   Lazenby, Audrey J ^c   Cohen, Lawrence K ^g   Finn, Christy C ^a   Clift, Shirley M ^g   Hauda, Karen M ^a   Beck, Lisa A ^a   Leiferman, Kristen M ^d   Owens Jr , Albert H ^a   Piantadosi, Steven ^a   Dranoff, Glenn ^f   Mulligan, Richard C ^e   Pardoll, Drew M ^a   Marshall, Fray F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MAYO CLINIC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR BASIC PROTEIN; VIRUS VECTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG SAFETY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADERMAL DRUG ADMINISTRATION; IRRADIATION; KIDNEY CARCINOMA; NEPHRECTOMY; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR IMMUNITY; VACCINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; DEFECTIVE VIRUSES; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; VACCINATION;

EID: 0030944023     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Mulligan, R. C. The basic science of gene therapy. Science (Washington DC), 260: 926, 1993.
2. Jaffee, E. M., Hurwitz, H., and Pardoll, D. M. Gene modifications of tumors. In: V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, Ed. 2, Vol. 774, p. 84. J. B. Lippincott, 1995.
3. Rosenberg, S. A. Newer approaches to cancer treatment. In: V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, Ed. 4, Vol. 2598, p. 13. J. B. Lippincott, 1993.
4. Tepper, R. I., Pattengale, P. K., and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57: 503-512, 1989.
5. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, B. Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
6. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172: 1217-1224, 1990.
7. Asher, A. L., Mule, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M., and Rosenberg, S. A. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J. Immunol., 146: 3327-3334, 1990.
8. Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hirofumi, H. Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
9. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, E., Karasuyama, H., Baker, M., and Pardoll, D. Treatment of established renal cancer by tumor cells engineered to secrete Interleukin-4. Science (Washington DC), 254: 713-716, 1991.
10. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
11. Jaffee, E. M., Lazenby, A., Meurer, J., Marshall, F., Hauda, K. M., Counts, C., Hurwitz, H., Simons, J. W., Levitsky, H. I., and Pardoll, D. M. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J. Immunother., 18: 1-9, 1995.
12. Carducci, M. A., Ayyagari, S. R., Sanda, M. G., and Simons, J. W. Gene therapy for human prostate cancer. Cancer (Phila.), 75: 2013-2020, 1995.
13. Vieweg, J., Rosenthal, F. M., Bannerji, R., Heston, W. D., Fair, W. R., Gansbacher, B., and Gilboa, I. Immunotherapy for prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54: 1760-1765, 1994.
14. Jaffee, E. M., Thomas, M. C. Huang, A. Y-C., Hauda, K. M., Levitsky, H. I., and Pardoll, D. M. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother., 19: 1-8, 1996.
15. Levitsky, H. I., Montgomery, J., and Ahmadzadeh, M. Immunization with GM-CSF-transduced, but not B7-1-transduced lymphoma cells primes idiotype specific T cells and generated potent systemic anti-tumor immunity. J. Immunol, in press, 1997.
16. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muratmatsu, S., and and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
17. Huang, A., Columbek, P., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., and Levitsky, H. I. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
18. Jaffee, E. M., Dranoff, G., Cohen, L. K., Hauda, K. M., Clift, S., Marshall, F. F., Mulligan, R. C., and Pardoll, D. M. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res., 53: 2221-2226, 1993.
19. Berns, A., Cohen, L., Donehower, R. C., Dranoff, G., Hauda, K. M., Jaffee, E. M., Lazenby, A. J., Levitsky, H. I., Marshall, F. F., Mulligan, R. C., Nelson, W. G., Owens, A. H., Pardoll, D. M., Parry, G., Partin, A. H., Piantadosi, S., Zabora, J. R., and Simons, J. W. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Recombinant DNA Advisory Committee Protocol, active as of 12/93. Hum, Gene Then, 6: 347-368, 1995.
20. Danos, O., and Mulligan, R. C. Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA, 85: 6460-6465, 1988.
21. Walther, M. M., Alexander, R. B., Weiss, G. H., Venzon, D., Herman, A., Pass, H. I., Linehan, W. M., and Rosenberg, S. A. Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urology, 42: 250-259, 1993.
22. Sokol, J. E. 1975 measurement of delayed skin test responses. N. Engl. J. Med., 29: 501, 1995.
23. McCune, C. S., O'Donnell, R. W., Marquis, D. M., and Sahasrabudhe, D. M. Renal cell Carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother., 32: 62-66, 1990.
24. Oren, M. E., and Herberman, R. B. Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumor cells. Clin. Exp. Immunol., 9: 45-56, 1977.
25. Hoover, H. C., Jr., Surdyke, M-, Dangel, R. B., Peters, L. C., and Hanna, M. G., Jr. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: bacillus Calmette-Guerin vaccine. Cancer Res., 44: 671-676, 1984.
26. Berd, D., Maguire, H. C., Jr., and Mastrangelo, M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res., 46: 2572-2577, 1986.
27. Berd, D. J., Maguire, J. C., Jr., McCue, P., and Mastrangelo, M. J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol., 8: 1858-1867, 1990.
28. Beck, L. A., Stellato, L., Beall, T., Schall, D., Leopold, C. A., Bickel, F. Baroody, B., Bocherner, B. S., and Schleimer, R. P. Detection of chemokine RANTES and endothelial adhesion molecules in nasal polyps. J. Allergy Clin. Immunol., 98: 766-774, 1996.
29. Peters, M. S., Schroeter, A. L., Kephart, G. M., and Gleich, G. J. Localization of eosinophil granule major basic protein in chronic urticaria. J. Invest. Dermatol., 81: 39-45, 1983.
30. Leiferman, K. M., Ackerman, S. J., Sampson, H. S., Haugen, P. Y., Venecie, G., and Gleich, G. J. Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N. Engl. J. Med., 313: 282-293, 1985.
31. Perez, G. L., Peters, M. S., Reda, A. M., Butterfield, J. H., Peterson, E. A., and Leiferman, K. M. Mast cells, neutrophils and eosinophils in prurigo nodularis. Arch. Dermatol., 129: 861-870, 1993.
32. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., DePlaen, E., Vandeneynde, B., Khuth, A., and Boon, T. A gene encoding an antigen recognized cytotoxic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1648, 1991.
33. Gaugler, B. Van den Eynde, B., Van der Bruggen, R. P., Romero, P., Gaforio, J. J., DePlaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
34. Brichard, V., Van Pel, A., Wolfel, T., DePlaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
35. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
36. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Maltei, S., DePlaen, E., Lurquin, C., and Szikora, J. P. A new gene coding for a differentiation antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
37. Bakker, A. B. H., Schreurs, M W. J., de Boer A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
38. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabonowitz, J., Engelhard, V. H., Hunt, D. F., and Sling-Luff, C. L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
39. Coulie, P., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Buon, T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA, 92: 7976-7980, 1995.
40. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
41. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, F., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
42. Robbins, P., El-Gamil, M., Kawakami, Y., and Rosenberg, S. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54: 3124-3126, 1994.
43. Bernhard, H., Karbach, J., Wolfel, T., Busch, P., Storkel, S., Stockle, M. Wolfel, C., Seliger, B., Huber, C., Meyer, H., Zum Buschenfelde, K. H. Cellular immune response to human renal cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocyte (CTL) clones. Int. J. Cancer, 59: 837-842, 1994.
44. Mawhorter, S. D., Kazura, J. E., and Boom, W. H. Human eosinophils as antigen-presenting cells: relative efficiency for superantigen- and antigen-induced CD4+ T cell proliferation. Immunology, 81: 584-591, 1994.
45. Del Pozo, V., De Andres, B., Martin, E., Cardaba, B., Fernandez, J. C., Gallardo, S., Tramon, P., Leyva-Cobian, F., Palomino, P., and Lahoz, C. Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur. J. Immunol., 22: 1919-1925, 1992.
46. Lucey, D. R., Nicholson-Weller, A., and Weller, P. F. Mature human eosinophils have the capacity to express HLA-DR. Proc. Natl. Acad. Sci. USA, 86: 1348-1351, 1989.
47. Weller, P. F. The immunobiology of eosinophils. N. Engl. J. Med., 324: 1110-1118, 1991.
48. Gleich, G. J., Adolphson, M. S., and Leiferman, K. M. The biology of the eosinophilic leukocyte. Annu. Rev, Med., 44: 85-101, 1993.
49. Del Prete, G. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy (Cph.), 47: 450-455, 1992.
50. Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A. Role of cytokines and CD4+ T cell subsets in the regulation of parasite immunity and disease. Immunol. Rev., 112: 161-183, 1989.